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Abstract The category of disease-modifying anti-rheu-
matic drugs (DMARDs) emerged in the 1970s to describe
drugs capable of altering the long-term destructive course
of arthritis. It became a core concept in rheumatology’s
reorientation towards pharmaceuticals in the late twentieth
century. By examining the earliest use of the term ‘‘dis-
ease-modifying’’ in scientific publications, this paper
identifies the drugs that the category described when it first
emerged. Leaning on systematic reviews of each of these
drugs towards the end of their career in rheumatology, it
then establishes that posterity would not recognize any of
these early DMARDs as capable of altering the long-term
course of the disease. The notion of disease-modifying
drugs was thus originally used to categorize drugs that
were not disease-modifying. Instead of interpreting this
inconsistency as an anomaly, the paper argues that the
DMARD category may have gained currency because it
allowed a number of actors to respond pragmatically to an
ongoing crisis in the pharmacological approach to treating
arthritis. The term offered to conjure prospects of disease-
modifying effects regardless of drugs&actual capacities, and
thus to semantically solve the tensions between needs and
means that characterized rheumatology at the time. While
shedding light on a pivotal moment in the history of
rheumatology, the paper also models an approach to
understanding drug categories as meaning-making mecha-
nisms by which people can mediate the sometimes uneasy
connections that exist between medical practice and
science.
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Introduction
During a drug company symposium held at St. Bartholo-
mew’s Hospital in London in the mid-1970s, J. Michael
Gumpel from Northwick Park Hospital’s Rheumatic Study
Group presented his views on treating rheumatoid arthritis
(RA) with cyclophosphamide, gold and penicillamine.
From his paper, which opened by stating that gold appeared
to be ‘‘the disease-modifying drug of first choice’’ (Gumpel
1976), it seems that the notion of disease-modifying drugs
was already established. When asked almost 40 years later,
Gumpel suggested that the notion might even have
emerged years before, with the introduction of penicil-
lamine as an anti-rheumatic agent.1 And yet, his paper from
1976 is the earliest example of the usage in an academic
publication of the phrase ‘‘disease-modifying’’ that I have
been able to identify (Buer 2015).
Like the NSAID category had previously emerged to
demarcate against steroids (Buer 2014), the category that is
today known as disease-modifying anti-rheumatic drugs
(DMARDs) emerged in the 1970s to separate several sec-
ond-line drugs from the NSAIDs, which were known only
to affect the symptoms of RA. In the treatment of a disease
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that would eat away at the joints if left to run its natural
course, the new category articulated an idea of drugs
capable of altering the disease’s long-term outcome, and of
preventing bone erosion (Paulus 1982, p. 29).2 As that
capacity became the emerging category’s defining feature,
the category negotiated a niche between the unattainable
cure and the insufficiencies of symptom-relief, and opened
a new frontier for anti-rheumatic drugs.
In the decades that followed Gumpel’s paper, the two
categories NSAID and DMARD came to constitute a basic
structural premise for rheumatological thinking and treat-
ment. NSAIDs were often identified with the first step,
while the more toxic and presumably also more potent
DMARDs were used as a second step and beyond. While
this framework creates a sense of continuity, there was
nevertheless a fundamental discontinuity between the
drugs initially categorized as disease-modifying and those
belonging to that category some 40 years later. By identi-
fying the drugs that the term was used to categorize when it
first appeared, and by reviewing the evidence that existed
for their disease-modifying capacities towards the end of
their career in rheumatology, I have found that none of the
drugs that the term DMARD initially described were ever
to be proven to have the disease-modifying properties that
defined them. And yet, instead of offering a criticism of the
category and its uses, I shall argue that it worked to solve
deep-seated tensions that existed in rheumatology, and was
thus instrumental in laying the semantic foundations upon
which rheumatology, in the last decades of the 20th cen-
tury, reinvented itself as a discipline focused on
pharmacological treatment.
The prototypical DMARDs
In 1976, Gumpel had used the term ‘‘disease-modifying’’ to
group together three drugs, namely cyclophosphamide,
gold and penicillamine.3 Gumpel’s paper reviewed his
team’s results with drugs with which they had experience,
and did not aim at outlining the entire group. In 1980,
however, three other reviews aimed at doing just that
(Bunch and O’Duffy 1980; Hunneyball 1980; Anastassi-
ades 1980). If one examines Gumpel’s text together with
these reviews, one finds that the term ‘‘disease-modifying’’
(and the interchangeably used term ‘‘remission-inducing’’4)
did in fact serve to group together a plethora of pharma-
cological compounds, most of which were either in
marginal use or under investigation. The most compre-
hensive review, written by British bio-chemist Ian M.
Hunneyball, did for instance list frentizole, brenedin,
CCA,5 RMI 9563,6 and tilorone; complement inhibitors,
coumarin, and orgotein; ICI 55,897/Clozic, dapsone, ben-
zoylacetonitrile and sulfasalazine, as ‘‘currently under
investigation’’—and nitrogen mustard, chlorambucil and
methotrexate as having been ‘‘used at one time or another’’.
This landscape may seem bewildering. Yet, if one jux-
taposes the few drugs on which the four reviews chose to
focus, one gets a surprisingly consistent picture (see
Fig. 1). The five drugs, or kinds of drugs, that thus come to
the fore as the drugs for which the emergent label was first
and foremost used were gold, cyclophosphamide, penicil-
lamine, azathioprine, and the quinoline anti malarias
chloroquine and hydroxychloroquine.7 Based on the
assumption that it was the position of these drugs in con-
temporary discourse that called for the establishment of the
new category, I have chosen to call these drugs the pro-
totypical DMARDs.8 Among the five, it was gold, which
Gumpel designated as the disease-modifying drug ‘‘of first
choice’’, that was going to form ‘‘the backbone’’ of
DMARD therapy (Abruzzo 1986, p. 274). Gold was also
the drug against which all new contenders to the DMARD
status were to be measured, until it was challenged and
eventually superseded by methotrexate in the 1980s (Case
2001a, p. 128).
2 According to certain sources, the DMARDs could even be expected
to repair the joints (see Case 2001a, p. 128).
3 Gumpel used the terms ‘‘gold’’ and ‘‘penicillamine.’’ This requires
some clarification. Over the years, a number of different gold
compounds have been used in the treatment of RA (see Abruzzo
1986, p. 274; Klinkhoff 2005, p. 978; Kean and Kean 2008, p. 113),
most commonly the aurothiolates gold sodium thioglocose (GSTG/
AGT) and gold sodium thiomalate (ATM/GSTM). In rheumatological
discourse, the terms ‘‘gold’’ and ‘‘gold salts’’ have been used to refer
to any of these compounds. When I use the term ‘‘gold’’ in this paper,
it is thus to designate the members of the group of gold compounds or
complexes that have been used in RA. Penicillamine, in turn, exists in
different forms (L-penicillamine, DL-penicillamine and D-penicil-
lamine). In medical treatment, it is, however, only the D isomer
that has been successfully used (Howard-Lock et al. 1986). All
reference made to penicillamine in this text shall therefore be
references to D-penicillamine.
4 See Buer (2015) for details.
5 N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt.
6 DEAP fluoranthene (Bis(3-(diethylamino)propyl) 3,9-fluoran-
thenedicarboxylate dihydrochloride).
7 The drug levamisole was among the six compounds on which
Hunneyball focused his review, and also Anastassiades made mention
of it. This drug, first used in RA in 1975, was still undergoing testing
in 1980 (Anastassiades 1980, p. 410), and judging from its absence in
later reviews (Whitehouse 2005; Case 2001a, b), it seems it never
came to play any significant role in the treatment of RA. Its mention
in by Hunneyball and Anastassiades may thus be accidental, guided
by vested interests, or in other ways not representative to rheuma-
tological thinking at the time.
8 My approach here relies on ethnolinguist notion of prototypical or
core references, and David Kronenfeld’s description of the conditions
under which new labels emerge (see Kronenfeld 1996, p. 186).
186 J. K. Buer
123
Inquiry and evidence
The efficacy of several prototypical DMARDs had already
been questioned before the category emerged, and still in
the early 1990s, evidence for disease-modifying capacities
for any so-called DMARD was scarce (Anastassiades 1980,
p. 410; Scott et al. 1987; Epstein 1989; Capell and Brzeski
1992, p. 424; Edmonds et al. 1993, p. 336). As research
accumulated, the prototypical DMARDs became the object
of closer scrutiny, and more vivid criticism. This was in
particular the case with gold (Epstein 1989). Some critics
went so far as to argue that the only two characteristics
shared by the drugs known as DMARDs were the ability to
modify the symptoms of RA, and a delayed onset of action
compared to the NSAIDs and steroids (Edmonds et al.
1993, p. 336).9
Towards the end of the 1990s, the Cochrane collabo-
ration therefore subjected the prototypical DMARDs to
systematic reviews. Gold was first to be reviewed (Clark
et al. 1997); reviews of the other four followed.10 Each of
the five prototypical DMARDs had by this time been used
in RA for between 25 and 65 years, and a large number of
tests had been performed. Ample data had accumulated to
document that severe adverse effects were associated with
four out of five drugs; only the quinoline hydroxy-
chloroquine came out with a benign side effect profile.11
In addition, all the reviews concluded there was a statis-
tically significant benefit, most also finding a clinical
benefit in disease activity or short-term treatment. There
was, however, a catch: The Cochrane collaboration failed
to review the prototypical DMARDs as DMARDs.
If one were to demonstrate that an airplane functioned
according to expectations, one would at a minimum need
to document the plane’s essential capacity to fly. Docu-
mentation of other capacities, such as the capacity to taxi
down the runway, might well be appreciated, but would
not provide reason to concluding on proper functioning of
the plane as such. Much in the same way, one might
expect that the proof of efficacy of a DMARD would
require the disease-modifying capacities that defined the
category to be documented. A demonstration of any other
kind of effect might be well appreciated, but would not
suffice to conclude that the DMARD worked as a
DMARD.
While the Cochrane collaboration found statistical and
even clinical significance to have been documented for
several outcome measures in all the prototypical
DMARDs, these were measures of short-term effects on
the symptoms of the disease and on surrogate markers, and
thus not indicative of long-term disease-modifying effi-
cacy. It seems that despite the prototypical DMARDs’
widespread and continuous use over several decades, the
Cochrane collaboration reviewers had not been able to find
evidence to support the notion that any had the capacity to
prevent bone erosion, or otherwise modify the long-term
course of the disease. In the reviews of penicillamine and
of azathioprine, there were indications that attempts to
assess long-term effects had been made. The other reviews
remained silent on the question. None of the reviews
pointed this crucial fact out.
Fig. 1 The prototypical DMARDs. Drugs marked with ‘9’ were
subject to review as either ‘‘disease-modifying’’ or ‘‘remission-
inducing’’ drugs in the four publications that first employed these
labels (Gumpel 1976; Bunch and O’Duffy 1980; Anastassiades 1980;
Hunneyball 1980). In addition to the drugs on which these reviews
focused, a number of other compounds were mentioned either for
their anecdotal use (a) or as being researched (r). In the category
(a) was the cancer drug methotrexate, which was later to become a
mainstay anti-rheumatic DMARD following the publication of a
study published by Hoffmeister (1983); its use in the treatment of RA
was going to be approved by the FDA in 1988. (See also Whitehouse
2005, p. 2936; Weinblatt 2013, p. 17)
9 In the WHO and the ILAR, a forceful attempt was made to replace
the DMARD category with a terminology that better reflected the
realities that years of testing had revealed, but the attempt was
unsuccessful (Buer 2015).
10 The other reviews appeared in 2000 (cyclophosphamide in Suarez-
Almazor, Belseck et al. 2000a; azathioprine in Suarez-Almazor,
Spooner and Belseck 2000a; penicillamine in Suarez-Almazor,
Spooner and Belseck 2000b). Chloroquine was not reviewed, while
its less toxic cousin hydroxychloroquine was (in Suarez-Almazor,
Belseck, Shea, Homik et al. 2000). Levamisole, which was by and
large discredited by that time, was not reviewed.
11 Rainsford and colleagues have recently published a detailed
discussion of hydroxychloroquine action, including that drug’s side
effect profile (see Rainsford et al. 2015, pp. 257–259 for details).
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The idea before the fact
Despite decades of use, no-one had thus managed to
demonstrate in ways that satisfied Cochrane’s criteria that
any of the prototypical DMARDs had the properties that
allegedly unified and defined them. By contrast, in the case
of methotrexate—which was reviewed together with the
prototypical DMARDs—Cochrane’s reviewers acknowl-
edged a 1999 trial as evidence for radiographic effect
(Strand et al. 1999; in Suarez-Almazor, Belseck et al.
2000b). In 1999, after some 25 years, that trial thus pro-
vided the DMARD category with a welcome mark of
factuality. In 1976, however, which is where our DMARD
story started, the publication that was going to announce
the advent of methotrexate in mainstream rheumatology
was still seven years ahead (Hoffmeister 1983). More-
over—and this is interesting—when Gumpel named gold
as the disease-modifying drug of first choice, this was a full
15 years after a long-awaited, large randomized double-
blind trial had failed to show any permanent long-term
effect of gold treatment, neither on bone erosion nor on
other parameters (ERC 1960, 1961), although it was able to
document effect on several short-term measurements.12 It
was also three years after a second study had failed to
produce evidence of long-term efficacy of gold (ARA
1973).13 When gold was first classified as a disease-mod-
ifying drug, it seems that the drug had already been shown
not to be just that. Gumpel, consequently, identified gold as
the ‘‘first choice’’ of something it was not.
Clearly, the emergence in the 1970s of the notion of
disease-modifying drugs cannot be well understood as
reflecting the actual capacities of the drugs it defined, or
evidence for such capacities. Quite on the contrary, I would
like to suggest the category may have emerged as a con-
sequence of pragmatic responses to a lack of such
evidence: The preceding decades had witnessed a dual
crisis in steroid and gold therapy. The toxicity of steroids
(Anastassiades 1980, p. 410; Case 2001a, p. 130) and
repeated failures to document the assumed long-term
effects of gold (ERC 1960, 1961; ARA 1973) threatened to
turn rheumatology into a sub-specialty deprived of drugs
by means of which to fulfill its promises. In this situation,
the notion of disease-modifying drugs and the curious ways
in which it was configured made it possible to confer
meaning—a particular disease-modifying identity—onto
the drugs it grouped. Assigning a drug to the category was
saying what regulators, physicians and patients should
expect from it. More precisely, it was claiming that the
drug was able to reduce damage and prevent RA’s devas-
tating long-term outcome.
Conjuring a world that does not yet exist
The large ERC and ARA trials had failed to document that
gold injections could modify the long-term course of the
disease, and in particular to stop the erosion of bone. Yet, it
seems, by means of long-term promises, the emergent
notion of disease-modifying drugs made it possible to
justify the continued use of gold, despite its important
toxicities, plausibly extending the career of gold as an anti-
rheumatic agent by several decades. Furthermore, as con-
tenders to DMARD status merely needed to demonstrate
equal benefit to that of gold injections, a number of sub-
stances for which disease-modifying capacities were never
to be documented could enter into circulation. In the
industry, separate DMARD discovery programs turned new
compounds into DMARDs by means of definition long
before any disease-modifying capacities could be proven,
and the category expanded to include a large number of
substances (as seen in Hunneyball 1980).
Although inconsistencies between the concept’s
semantic content and the properties of the drugs to which it
referred may be disconcerting to some, it is my opinion that
the category does not at all need to be considered an
anomaly. On the contrary, its inherent tensions and
idiosyncrasies and all its pragmatic potential seem to speak
as evidence of the creative efforts that produced and sus-
tained rheumatology in the latter half of the 20th century.
Concluding remarks
At the time when the notion of disease-modifying drugs
emerged, it was used to group drugs together according to
properties that people hoped their drugs would have. Part
12 In its preliminary report, published at 18 months, the Empire
Rheumatism Council (ERC) reported significant differences between
the gold treated group and the control on several short-term
parameters. However, for the measurement for bone erosion (i.e.,
radiographic progression), no significant difference had been
recorded. Furthermore, at 30 months, nearly all difference had
disappeared also for the other parameters, as described in the final
report (ERC 1961, p. 333). In retrospect, it seems that this setback
was not been well appreciated at the time. It is also worth noting that
the results from the ERC trials have been and continue to be
misrepresented as though they were supporting the notion that gold
injections retard bone erosion. For example, Foye’s Principles of
medicinal Chemistry asserts that the ERC ‘‘…reported in 1961 that
sodium aurothiomalate was effective in slowing down the develop-
ment of progressive joint diseases’’ (Foye et al. 2008, p. 989) (For a
more critical interpretation of the ERC trial results see Epstein 1989,
p. 1291).
13 In phase 1 of this study, which was organized by the Cooperating
Clinics Committee of the American Rheumatism Association (ARA),
erythrocyte sedimentation rate (ESR) was the only measurement that
reached statistical significance. In phase 2, designed to evaluate
possible benefits of maintenance therapy, all measures failed to reach
statistical significance (See also Epstein 1989, p. 1292).
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of the term’s pragmatic potential seems to have lain in how
it projected a promise of radical improvement into the
future and beyond scope of trials. A promise of improved
health years ahead will always take years to evaluate. As
demands for evidence here and now were thus made
irrelevant, rheumatology’s chronic inability to determine if
drugs worked was literally transformed into a cultural
resource of immediate and pragmatic value.14 By trans-
lating hopes and ambitions into pharmacological facts, the
notion of disease-modifying drugs thus helped bridge the
gap that existed between rheumatology’s limited means
and the dire needs the discipline was set to meet. Not that
the use of the term stopped bone erosion, of course, but the
concept’s ability to confer an aura of disease-modifying
capacities onto a range of substances made it possible to
create a world ‘‘more dreamlike and sweeter than anything
that exists’’ (Tsing 2005, p. 58)—a world where the
inventory of presumably powerful anti-rheumatic drugs
over and again escaped depletion. While the erosion of
bone progressed as before, the DMARD concept thus
efficaciously prevented the erosion of hope in the treatment
of RA. This allowed the rheumatological enterprise to
thrive and prosper, and rheumatology to reinvent itself as
the drug-focused discipline it is today.
Over the years, it seems, drugs with actual disease-
modifying capacities have joined the DMARD family. Yet,
even in light of recent therapeutic advances, there is little
reason to believe that the notion of disease-modifying
drugs has lost its capacity to shape perceptions of anti-
rheumatic treatments. Rheumatology’s semantic resources
may in fact have increased in complexity and efficacy in
parallel to the development of its pharmacological ones. As
in the past, it may therefore still today be difficult to dis-
cern the threshold beyond which rheumatological jargon
ceases to help us describe reality, and instead seduces us to
create it in our own minds. Those aspiring to properly
assess the efficacy even of novel anti-rheumatic drugs may
hence benefit from keeping in mind the place that seman-
tics has occupied in modern rheumatology. The more
general audience may appreciate the example of the
DMARD as rheumatology’s contribution to the study of
those mechanisms by which medical thought operates.
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